CPT 81441: Genetic Panel for Inherited Bone Marrow Failure Syndromes
Commercial payers pay $2366 on average nationally for this procedure.
CPT code 81441 describes a targeted genomic sequence analysis panel for inherited bone marrow failure syndromes that analyzes a blood specimen for at least 30 genes to detect germline mutations associated with disorders such as Fanconi anemia; service type: molecular diagnostic targeted gene panel, typical site of service: clinical laboratory or pathology laboratory with physician interpretation.
Customize your policy alerts
Sign up for cpt 81441 policy alerts
Get alerted when payer policies referencing 81441 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
For CPT 81441, Blue Cross Blue Shield and Cigna show wider commercial rate dispersion while Aetna and BUCA are tighter. Calculating the interquartile ranges (P75 minus P25) yields: Blue Cross Blue Shield $1,167.00 ( $3,019.90 - $1,852.90 ), Cigna $1,676.40 ( $2,958.00 - $1,281.60 ), UnitedHealth Group $1,469.10 ( $2,938.20 - $1,469.10 ), Aetna $742.00 ( $2,039.00 - $1,297.00 ), and BUCA $1,231.40 ( $2,832.50 - $1,601.10 ). These differences indicate Cigna and Blue Cross Blue Shield have the widest spread, while Aetna exhibits the tightest interquartile range.
Average commercial pricing centered on BUCA at a mean of $2,365.80 provides a midpoint against which individual payers vary: Aetna’s mean is $1,641.90, UnitedHealth Group’s mean is $2,422.40, Cigna’s mean is $2,332.30, and Blue Cross Blue Shield’s mean is $2,599.50. Minimum and maximum extremes are notable for several payers (for example, Blue Cross Blue Shield max $8,709.40 and Aetna min $372.10), underscoring that outlier contracts can push realized reimbursements well beyond interquartile spreads.